sx-682
Showing 1 - 6 of 6
Metastatic Colorectal Cancer Trial run by the National Cancer Institute (NCI) (Retifanlimab, Therapeutic CEA, Brachyury and MUC1
Not yet recruiting
- Metastatic Colorectal Cancer
- Retifanlimab
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Dec 4, 2023
Pancreatic Cancer Trial in Baltimore (Tislelizumab, SX-682)
Not yet recruiting
- Pancreatic Cancer
- Tislelizumab
- SX-682
-
Baltimore, MarylandJohns Hopkins SKCCC
Jan 23, 2023
Metastatic Cancer, Solid Tumors Trial run by the NCI (SX-682, M7824, MVA-BN-CV301)
Active, not recruiting
- Metastatic Cancer
- Solid Tumors
- SX-682
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 11, 2022
MDS Trial in Orlando, Tampa, Baltimore (SX-682)
Recruiting
- Myelodysplastic Syndromes
- SX-682
-
Orlando, Florida
- +2 more
Feb 18, 2022
Melanoma Stage III, Melanoma Stage IV Trial in Boston, Rochester, Houston (SX-682, Pembrolizumab)
Recruiting
- Melanoma Stage III
- Melanoma Stage IV
- SX-682
- Pembrolizumab
-
Boston, Massachusetts
- +4 more
Jan 26, 2022
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Trial in Rochester (SX-682, Nivolumab Injectable Product)
Recruiting
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Cancer
- SX-682
- Nivolumab Injectable Product
-
Rochester, New YorkUniversity of Rochester
Dec 14, 2021